IPSC
Century Therapeutics, Inc.
$2.25
+0.45%
$405.8M
No data for this timeframe.
Vol
Market Cap$405.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders32 funds
Inst. Value$130.7M
Inst. Activity7 buys / 3 sells
Insider Activity0B / 8S
Insider Net $-$48.3K
SEC Reports8
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001850119·Prev Close $2.24
Recent Activity
Jun 12, 2026
SEC
Two insiders at Century Therapeutics (IPSC) sold a combined ~$1,632 in open-market sales on June 8, 2026, while five dir
CLUSTER — Impact 2/10
Jun 11, 2026
Insider
Lee Han Myung was granted 74,000 shares
Director
Jun 11, 2026
Insider
Blackwell Kimberly was granted 74,000 shares
Director
Jun 11, 2026
Insider
Quimi Daphne was granted 74,000 shares
Director
Jun 9, 2026
SEC
Two insiders at Century Therapeutics sold small open-market positions totaling ~$1.6K on June 8, 2026, while the CEO had
CLUSTER — Impact 2/10
Jun 8, 2026
fda
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
<p align="left">PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Centu
May 13, 2026
SEC
Century Therapeutics reported Q1 2026 results with a net loss of $21.6M vs net income of $76.6M in Q1 2025, driven by th
8-K — Impact 4/10
Inst.
RA CAPITAL MANAGEMENT, L.P. — NEW
17,754,430 shares ($40.1M)
Price Targets
$4.75
+111.1% upside
Strong Buy
Current $2.25
Low $2.00
Median $4.50
High $8.00
4 analysts
$2.00
$8.00
Analyst Ratings
2Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Mizuho | INITIATE | Outperform |
| Apr 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 20, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 ▲ +22.2% | $-0.13 — $-0.11 | 69% YoY | 3 |
| Next Q | $-0.12 ▲ +17.8% | $-0.14 — $-0.11 | 61% YoY | 3 |
| Current FY | $-0.46 ▲ +26.4% | $-0.55 — $-0.37 | -1290% YoY | 4 |
| Next FY | $-0.46 ▲ +13.7% | $-0.56 — $-0.28 | 1% YoY | 4 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two insiders at Century Therapeutics (IPSC) sold a combined ~$1,632 in open-market sales on June 8, 2026, while five dir
Jun 12, 2026
NEUTRAL
CLUSTER
2/10
Two insiders at Century Therapeutics sold small open-market positions totaling ~$1.6K on June 8, 2026, while the CEO had
Jun 9, 2026
NEUTRAL
Press
3/10
Century Therapeutics announced an oral presentation at the ADA 86th Scientific Sessions (June 5-8, 2026) highlighting pr
Apr 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $40.1M | NEW |
| RTW INVESTMENTS, LP | $19.7M | NEW |
| Point72 Asset Management, L.P. | $13.5M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $12.9M | — |
| BALYASNY ASSET MANAGEMENT L.P. | $11.3M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | Lee Han | A | $0.00 |
| Jun 11, 2026 | Blackwell Kimberly | A | $0.00 |
| Jun 11, 2026 | Quimi Daphne | A | $0.00 |
| Jun 11, 2026 | Murphy Martin | A | $0.00 |
| Jun 11, 2026 | Riva Alessandro | A | $0.00 |
32 institutional holders with $130.7M total value (57,843,791 shares) as of 2026-Q1. Top holders: RA, RTW, Point72. Net buying activity: 7 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 17,754,430 | $40.1M | 30.7% | NEW |
| 2 | RTW INVESTMENTS, LP | 8,695,652 | $19.7M | 15.0% | NEW |
| 3 | Point72 Asset Management, L.P. | 5,964,678 | $13.5M | 10.3% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 5,686,204 | $12.9M | 9.8% | — |
| 5 | BALYASNY ASSET MANAGEMENT L.P. | 5,017,733 | $11.3M | 8.7% | NEW |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,789,538 | $8.6M | 6.6% | DOUBLED +106.1% |
| 7 | Woodline Partners LP | 3,043,478 | $6.9M | 5.3% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 2,371,430 | $5.4M | 4.1% | ADD +64.1% |
| 9 | BlackRock, Inc. | 1,524,422 | $3.4M | 2.6% | DOUBLED +153.3% |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 906,827 | $2.0M | 1.6% | TRIM -32.8% |
| 11 | VANGUARD FIDUCIARY TRUST CO | 692,963 | $1.6M | 1.2% | — |
| 12 | MARSHALL WACE, LLP | 673,584 | $1.5M | 1.2% | TRIM -61.2% |
| 13 | STATE STREET CORP | 386,723 | $874.0K | 0.7% | DOUBLED +203.4% |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 226,687 | $512.3K | 0.4% | — |
| 15 | GOLDMAN SACHS GROUP INC | 210,482 | $475.7K | 0.4% | — |
| 16 | BANK OF AMERICA CORP /DE/ | 145,099 | $327.9K | 0.3% | DOUBLED +27537.9% |
| 17 | BARCLAYS PLC | 120,232 | $271.7K | 0.2% | NEAR_EXIT -100.0% |
| 18 | Brevan Howard Capital Management LP | 96,641 | $218.4K | 0.2% | — |
| 19 | RAYMOND JAMES FINANCIAL INC | 91,323 | $206.4K | 0.2% | — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 79,415 | $179.5K | 0.1% | TRIM -39.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 17,754,430 | — | $40.1M | 2026-Q1 |
| RTW INVESTMENTS, LP | NEW | — | 8,695,652 | — | $19.7M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 5,017,733 | — | $11.3M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 1,838,700 | 3,789,538 | +106.1% | $8.6M | 2026-Q1 |
| BlackRock, Inc. | DOUBLED | 601,866 | 1,524,422 | +153.3% | $3.4M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,349,200 | 906,827 | -32.8% | $2.0M | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 127,443 | 386,723 | +203.4% | $874.0K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 525 | 145,099 | +27537.9% | $327.9K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 59,800 | 25,300 | -57.7% | $57.2K | 2026-Q1 |
| FMR LLC | NEAR_EXIT | 71,540 | 8,779 | -87.7% | $19.8K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 911,446 | 1,495,916 | +64.1% | $1.5M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,586,900 | 1,349,200 | -47.8% | $1.3M | 2025-Q4 |
| FMR LLC | TRIM | 192,139 | 71,540 | -62.8% | $71.2K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 8,151 | 254 | -96.9% | — | 2025-Q3 |
| BARCLAYS PLC | NEAR_EXIT | 12,197 | 1 | -100.0% | — | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 2,022,500 | 2,586,900 | +27.9% | $1.3M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 572,544 | 911,446 | +59.2% | $453.9K | 2025-Q3 |
| BlackRock, Inc. | TRIM | 924,683 | 599,656 | -35.2% | $298.6K | 2025-Q3 |
| CITADEL ADVISORS LLC | ADD | 186,534 | 360,825 | +93.4% | $179.7K | 2025-Q3 |
| FMR LLC | NEAR_EXIT | 1,020,614 | 192,139 | -81.2% | $95.7K | 2025-Q3 |
| MARSHALL WACE, LLP | TRIM | 139,707 | 54,161 | -61.2% | $27.1K | 2025-Q3 |
| Jain Global LLC | TRIM | 40,276 | 11,241 | -72.1% | $5.6K | 2025-Q3 |
| NISA INVESTMENT ADVISORS, LLC | TRIM | 1,262 | 883 | -30.0% | $440.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 3,290 | 598 | -81.8% | $298.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 28,026 | 337 | -98.8% | $168.00 | 2025-Q3 |
9 unique insiders with 28 transactions. Net insider value: -$48.3K ($0.00 bought, $48.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Lee Han Myung | Director | AWARD | 74,000 | — | — |
| Jun 11, 2026 | Blackwell Kimberly | Director | AWARD | 74,000 | — | — |
| Jun 11, 2026 | Quimi Daphne | Director | AWARD | 74,000 | — | — |
| Jun 11, 2026 | Murphy Martin Patrick | Director | AWARD | 74,000 | — | — |
| Jun 11, 2026 | Riva Alessandro | Director | AWARD | 74,000 | — | — |
| Jun 8, 2026 | Carr Douglas | SVP Finance & Operations | SELL | 249 | $2.11 | $525.64 |
| Jun 8, 2026 | Russotti Gregory | See Remarks | SELL | 524 | $2.11 | $1.1K |
| Jun 5, 2026 | Pfeiffenberger Brent | President and CEO | TAX W/H | 463 | $2.13 | $986.19 |
| May 15, 2026 | Pfeiffenberger Brent | President and CEO | TAX W/H | 31,172 | $2.34 | $72.9K |
| May 4, 2026 | Carr Douglas | SVP Finance & Operations | SELL | 264 | $2.34 | $618.02 |
| Apr 1, 2026 | Cowan Chad | Chief Scientific Officer | TAX W/H | 1,365 | $2.19 | $3.0K |
| Mar 12, 2026 | Carr Douglas | SVP Finance & Operations | SELL | 7,043 | $2.55 | $18.0K |
| Mar 12, 2026 | Russotti Gregory | See Remarks | SELL | 10,076 | $2.55 | $25.7K |
| Mar 11, 2026 | Cowan Chad | Chief Scientific Officer | TAX W/H | 1,431 | $2.73 | $3.9K |
| Mar 11, 2026 | Pfeiffenberger Brent | President and CEO | TAX W/H | 55,397 | $2.73 | $151.2K |
| Mar 9, 2026 | Russotti Gregory | See Remarks | SELL | 479 | $2.54 | $1.2K |
| Mar 9, 2026 | Carr Douglas | SVP Finance & Operations | SELL | 247 | $2.54 | $626.39 |
| Mar 6, 2026 | Pfeiffenberger Brent | President and CEO | TAX W/H | 463 | $2.56 | $1.2K |
| Feb 3, 2026 | Carr Douglas | SVP Finance & Operations | SELL | 323 | $1.82 | $588.51 |
| Feb 2, 2026 | Cowan Chad | Chief Scientific Officer | AWARD | 135,000 | — | — |
| Feb 2, 2026 | Cowan Chad | Chief Scientific Officer | AWARD | 265,000 | — | — |
| Feb 2, 2026 | Pfeiffenberger Brent | President and CEO | AWARD | 475,000 | — | — |
| Feb 2, 2026 | Pfeiffenberger Brent | President and CEO | AWARD | 945,000 | — | — |
| Feb 2, 2026 | Russotti Gregory | See Remarks | AWARD | 135,000 | — | — |
| Feb 2, 2026 | Russotti Gregory | See Remarks | AWARD | 265,000 | — | — |
| Feb 2, 2026 | Carr Douglas | SVP Finance & Operations | AWARD | 110,000 | — | — |
| Feb 2, 2026 | Carr Douglas | SVP Finance & Operations | AWARD | 225,000 | — | — |
| Dec 9, 2025 | Murphy Martin Patrick | Director | AWARD | 88,000 | — | — |
8 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 7 neutral. Avg impact: 3.4/10.
NEUTRAL
CLUSTER
2/10
Two insiders at Century Therapeutics (IPSC) sold a combined ~$1,632 in open-market sales on June 8,
Jun 12, 2026
NEUTRAL
CLUSTER
2/10
Two insiders at Century Therapeutics sold small open-market positions totaling ~$1.6K on June 8, 202
Jun 9, 2026
NEUTRAL
8-K
4/10
Century Therapeutics reported Q1 2026 results with a net loss of $21.6M vs net income of $76.6M in Q
May 13, 2026
NEUTRAL
PRESS-RELEASE
4/10
Century Therapeutics reported Q1 2026 EPS of -$0.11, beating the -$0.17 consensus by 35%, with zero
May 13, 2026
NEUTRAL
DEFA14A
2/10
Analysis based on filing metadata only — document content was unavailable. Century Therapeutics file
Apr 27, 2026
NEUTRAL
424B5
4/10
Century Therapeutics is conducting an at-the-market (ATM) offering of up to $131.6 million in common
Mar 26, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider share dispositions occurred at Century Therapeutics over the past week, includi
Mar 16, 2026
MIXED
8-K
6/10
Century Therapeutics reported its 2025 financial results and provided business updates, highlighted
Mar 12, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 2 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.75 mean target
+111.1% upside
Strong Buy (1.60)
$2.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $2.25 |
| Target Low | $2.00 |
| Target Mean | $4.75 |
| Target Median | $4.50 |
| Target High | $8.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.13 | $-0.11 | 69.3% | +22.2% | 2↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.12 | $-0.14 | $-0.11 | 61.5% | +17.8% | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-0.46 | $-0.55 | $-0.37 | -1289.7% | +26.4% | 2↑ 0↓ | $0.0B | -100.0% | 4 |
| Next FY 2027-12-31 |
$-0.46 | $-0.56 | $-0.28 | 0.5% | +13.7% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.117 | |
| 7d ago | $-0.117 | |
| 30d ago | $-0.150 | +0.033 |
| 60d ago | $-0.150 | +0.033 |
| 90d ago | $-0.227 | +0.110 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Mizuho | INITIATE | — | Outperform |
| Apr 21, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 8 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 2 | 8 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
fda
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
<p align="left">PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company develo
May 29, 2026
short_volume
Short Volume: IPSC — 80.1% short (0.4M / 0.5M)
Short: 428,488 | Exempt: 0 | TRF Vol: 534,737 | Short Ratio: 80.1% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: IPSC — 60.1% short (0.3M / 0.5M)
Short: 326,694 | Exempt: 9,051 | TRF Vol: 543,714 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
May 20, 2026
earnings_calendar
IPSC Q1 2026 Earnings Before Market Open — 2026-05-20
May 13, 2026
earnings
Century Therapeutics Reports First Quarter Financial Results and Business Updates
<p>PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced p
May 13, 2026
earnings_calendar
IPSC Q1 2026 Earnings Before Market Open — 2026-05-13
May 11, 2026
earnings_calendar
IPSC Q1 2026 Earnings Before Market Open — 2026-05-11
May 4, 2026
earnings_calendar
IPSC Q1 2026 Earnings Before Market Open — 2026-05-04
Apr 30, 2026
fda
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submi
Apr 17, 2026
short_volume
Short Volume: IPSC — 79.7% short (0.8M / 1.0M)
Short: 765,803 | Exempt: 116 | TRF Vol: 960,598 | Short Ratio: 79.7% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
short_volume
Short Volume: IPSC — 74.8% short (0.4M / 0.6M)
Short: 429,415 | Exempt: 0 | TRF Vol: 574,057 | Short Ratio: 74.8% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: IPSC — 81.6% short (0.6M / 0.7M)
Short: 561,086 | Exempt: 0 | TRF Vol: 687,810 | Short Ratio: 81.6% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: IPSC — 81.0% short (0.8M / 1.0M)
Short: 771,552 | Exempt: 0 | TRF Vol: 953,080 | Short Ratio: 81.0% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
short_volume
Short Volume: IPSC — 78.0% short (0.7M / 0.9M)
Short: 713,025 | Exempt: 6,311 | TRF Vol: 913,739 | Short Ratio: 78.0% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: IPSC — 92.1% short (0.8M / 0.8M)
Short: 750,784 | Exempt: 0 | TRF Vol: 814,907 | Short Ratio: 92.1% | Off-exchange volume (dark pool + OTC)